Raymond James analyst Steven Seedhouse maintains $Gilead Sciences (GILD.US)$ with a buy rating, and adjusts the target price from $93 to $103.
According to TipRanks data, the analyst has a success rate of 41.4% and a total average return of 10.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Gilead Sciences (GILD.US)$'s main analysts recently are as follows:
The company experienced a sales surge, propelled by robust performance within its HIV product line and higher-than-anticipated revenue from Veklury. The firm noted that the company's HIV business delivered a solid quarter characterized by sustained volume expansion and a beneficial product mix.
The company surpassed the third-quarter expectations, bolstered not only by Veklury but also by the performance of Biktarvy.
The company is perceived to be undergoing significant changes, focusing on its core strength as a pioneer in the field of antivirals. This shift is exemplified by the development of lenacapavir, which has the potential to become a cornerstone in HIV therapy and to broaden the scope of PrEP to a wider audience. The expansion of the PrEP market beyond traditional demographics is seen as an opportunity for growth. Furthermore, the company's oncology segment is advancing with robust growth in TRODELVY and a collaboration with a partner that is poised to deliver a top-tier CAR-T therapy for multiple myeloma.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
